[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336697-105":59,"doc-detail-336697-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tumor-angiogenesis-and-anti-angiogenic-therapy-review-aims-to-provide-historical-and-perspective-views","Tumor angiogenesis and anti-angiogenic therapy - review aims to provide historical and perspective views","","Anti-angiogenic drugs (AADs) that mainly interfere with the vascular endothelial growth factor-A signaling pathway have supported cancer therapy for two decades, accumulating extensive clinical experience and enabling both new drug development and expanded indications across multiple cancers via monotherapy and combination regimens. Despite this progress, outcomes with currently available AADs still need improvement, and more effective next-generation agents remain urgently required. This review integrates historical concept origins and AAD discovery with up-to-date clinical translation, highlighting mechanistic insights and future therapeutic directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-angiogenesis-and-anti-angiogenic-therapy-review-aims-to-provide-historical-and-perspective-views/336697/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-angiogenesis-and-anti-angiogenic-therapy-review-aims-to-provide-historical-and-perspective-views/336697.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which signaling pathway do anti-angiogenic drugs (AADs) mainly target?","Question",{"text":112,"@type":113},"They mainly target the vascular endothelial growth factor-A (VEGF-A) signaling pathway.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why does the review emphasize the need for improved and next-generation AADs?",{"text":117,"@type":113},"Clinical outcomes with currently available AADs still require improvement, and more effective next-generation AADs are urgently needed.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the core idea behind tumor angiogenesis as a therapeutic target?",{"text":121,"@type":113},"Tumor growth depends on angiogenesis, so inhibiting tumor angiogenesis can provide a new therapeutic approach for treating cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336697,1791269564,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Tumor angiogenesis and anti-angiogenic therapy  \nZiheng Guo1, Xu Jing2, Xiaoting Sun2,3, Shishuo Sun2,4, Yunlong Yang5, Yihai Cao2  \n1Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;  \n2Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm 17177, Sweden;  \n3Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vison and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China;  \n4Cancer Institute, the First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu 221000, China;  \n5Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.  \nAbstract  \nAnti-angiogenic drugs (AADs), which mainly target the vascular endothelial growth factor-A signaling pathway, have become a therapeutic option for cancer patients for two decades. During this period, tremendous clinical experience of anti-angiogenic therapy has been acquired, new AADs have been developed, and the clinical indications for AAD treatment of various cancers have been expanded using monotherapy and combination therapy. However, improvements in the therapeutic outcomes of clinically available AADs and the development of more effective next-generation AADs are still urgently required. This review aims to provide historical and perspective views on tumor angiogenesis to allow readers to gain mechanistic insights and learn new therapeutic development. We revisit the history of concept initiation and AAD discovery, and summarize the up-to-date clinical translation of anti-angiogenic cancer therapy in this field.  \nKeywords: Angiogenesis; Cancer; Angiogenesis inhibitors; Angiogenic factors; Vascular endothelial growth factors; Cancer therapy; Combined modality therapy  \nIntroduction  \nAs one of the largest tissue mass, blood vessels play critical roles in homeostasis maintenance, nutrient exchange, metabolism, and tissue growth through various mechanisms. The ubiquitous role of blood vessels suggests that targeting vessel growth may be an effective approach in treating a wide range of diseases. Among numerous bloodvessel-targeting therapies for various diseases, targeting tumor angiogenesis is the most validated therapy, with 20 years of clinical experience since the first US Food and Drug Administration-approved anti-angiogenic drug (AAD), which has been routinely used to treat a broad spectrum of solid tumors. The mechanism of tumor angiogenesis has been summarized by several comprehensive reviews, including reviews from the same series in this journal. This review provides historical views and references on tumor angiogenesis, and offers perspectives on new therapeutic development in the field of anti-angiogenic cancer therapy.  \nHistorical Overview of Tumor Angiogenesis  \nThe foundations for the field of tumor angiogenesis were laid by studies published a century ago. However, these  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code: | Website:\u003Cbr>[www.cmj.org](www.cmj.org) |\n|  | DOI:\u003Cbr>10.1097/CM9.0000000000003231 |\n\nstudies had little impact at the time, partly owing to technological limitations. In 1971, the young surgeon Judah Folkman[1] proposed inhibiting angiogenesis to treat cancer. This innovative idea provided a major impetus for research in this field and inspired many investigators. After decades of preclinical studies, various tumor-derived angiogenic factors have been identified, isolated, and studied extensively. In 2004, the US Food and Drug Administration approved bevacizumab, an anti-vascular endothelial growth factor (VEGF) neutralizing antibody, as the first AAD for treating metastatic colorectal cancer in humans.  \nFolkman’s concept of targeting tumor angiogenesis to treat cancer  \nIn the late 1960s and early 1970s, Folkman observed that solid tumors contained an exceptionally high number of fragile and hemorr","cbCaisozphws3Hzx","https://ap.wps.com/l/cbCaisozphws3Hzx","pdf",1377570,"English","# Abstract\n# Introduction\n# Historical Overview of Tumor Angiogenesis\n## Folkman’s concept of targeting tumor angiogenesis to treat cancer","[{\"question\":\"Which signaling pathway do anti-angiogenic drugs (AADs) mainly target?\",\"answer\":\"They mainly target the vascular endothelial growth factor-A (VEGF-A) signaling pathway.\"},{\"question\":\"Why does the review emphasize the need for improved and next-generation AADs?\",\"answer\":\"Clinical outcomes with currently available AADs still require improvement, and more effective next-generation AADs are urgently needed.\"},{\"question\":\"What is the core idea behind tumor angiogenesis as a therapeutic target?\",\"answer\":\"Tumor growth depends on angiogenesis, so inhibiting tumor angiogenesis can provide a new therapeutic approach for treating cancer.\"}]","Tumor angiogenesis and anti-angiogenic therapy - review aims to provide historical and perspective views | PDF",1790016239,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b522227739b483171755a6e1a60067e4.webp",983,1324,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/71a86fbfed6c0b717103215eef04381f.webp",982,1323,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/862720690c82244d529e921df8b48ebd.webp",981,1321,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65a963edc322a01ce5fa2404781a009c.webp",980,1320]